| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/19/2002 | CA2128287C Benzospiroalkene derivatives, their preparation process and pharmaceutical compositions containing them |
| 03/19/2002 | CA2106975C Process for conditioning of water-soluble substances |
| 03/19/2002 | CA2101076C Glycosphingolipids |
| 03/19/2002 | CA2050331C Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
| 03/19/2002 | CA2032797C Antithrombotic compounds |
| 03/15/2002 | CA2357155A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/14/2002 | WO2002021140A1 Nucleic acid sequences and proteins involved in cellular senescence |
| 03/14/2002 | WO2002020846A2 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure |
| 03/14/2002 | WO2002020841A2 5-hydroxytryptamine receptor gene polymorphisms and response to treatment |
| 03/14/2002 | WO2002020822A2 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | WO2002020788A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | WO2002020773A2 Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
| 03/14/2002 | WO2002020769A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | WO2002020767A2 G-csf analog compositions and methods |
| 03/14/2002 | WO2002020766A2 G-csf analog compositions and methods |
| 03/14/2002 | WO2002020763A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | WO2002020757A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | WO2002020736A2 Proteases |
| 03/14/2002 | WO2002020724A2 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | WO2002020723A2 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | WO2002020722A2 Methods and compositions for in vitro targeting |
| 03/14/2002 | WO2002020622A1 A mixture of non-sulfated fucose-based oligosaccharides, a cosmetic or pharmaceutical composition comprising said mixture and its use in cosmetics or pharmacy |
| 03/14/2002 | WO2002020621A1 Tetraphenylporphyrin derivatives and compositions comprising the same |
| 03/14/2002 | WO2002020619A2 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 03/14/2002 | WO2002020617A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 03/14/2002 | WO2002020570A2 Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening |
| 03/14/2002 | WO2002020569A2 Mammalian genes; related reagents and methods |
| 03/14/2002 | WO2002020563A2 RECEPTOR IN THE EDb FIBRONECTIN DOMAIN |
| 03/14/2002 | WO2002020553A1 NOVEL POLYMORPHIC FORM OF 17-β-(N-TER.BUTYL CARBAMOYL)-4-AZA-5-α-ANDROST-1-EN-3-ONE AND A PROCESS FOR PREPARING IT |
| 03/14/2002 | WO2002020536A1 Tetraphenylbacteriochlorin derivatives and compositions containing the same |
| 03/14/2002 | WO2002020530A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors |
| 03/14/2002 | WO2002020526A2 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 03/14/2002 | WO2002020524A1 Oxindole derivatives |
| 03/14/2002 | WO2002020514A1 Multivalent neuraminidase inhibitor conjugates |
| 03/14/2002 | WO2002020513A1 Oxindole derivatives |
| 03/14/2002 | WO2002020512A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 03/14/2002 | WO2002020495A2 Inhibitors of glycogen synthase kinase 3 |
| 03/14/2002 | WO2002020489A2 QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 03/14/2002 | WO2002020488A2 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 03/14/2002 | WO2002020484A1 Chemical compounds |
| 03/14/2002 | WO2002020483A1 Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 03/14/2002 | WO2002020482A1 1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl] methylpiperidine |
| 03/14/2002 | WO2002020479A1 Substituted oxindole derivatives as tyrosine kinase inhibitors |
| 03/14/2002 | WO2002020477A1 Apoptosis inhibitors |
| 03/14/2002 | WO2002020475A2 Inhibitors of serine protease activity of matriptase or mtsp1 |
| 03/14/2002 | WO2002020474A2 Resorcinol derivatives |
| 03/14/2002 | WO2002020465A2 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 03/14/2002 | WO2002020457A1 Dihydroxy open-acid salt of simvastatin |
| 03/14/2002 | WO2002020091A2 Antithrombotic compositions |
| 03/14/2002 | WO2002020090A2 Pharmaceutical compositions |
| 03/14/2002 | WO2002020058A1 Preparations for oral administration |
| 03/14/2002 | WO2002020056A2 Methods and compositions for producing a neurosalutary effect in a subject |
| 03/14/2002 | WO2002020040A1 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same |
| 03/14/2002 | WO2002020034A1 'pseudo'-native chemical ligation |
| 03/14/2002 | WO2002020033A1 Polymer-modified synthetic proteins |
| 03/14/2002 | WO2002020026A2 Treatment of drug resistant organisms with nitric oxide |
| 03/14/2002 | WO2002020023A1 Methods and compositions for potentiating cancer chemotherapeutic agents |
| 03/14/2002 | WO2002020020A1 Exemestane as chemopreventing agent |
| 03/14/2002 | WO2002020018A1 Tablets containing epinastine manufactured by direct compression |
| 03/14/2002 | WO2002020016A1 AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA α7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY |
| 03/14/2002 | WO2002020013A2 A method for treating allergies using substituted pyrazoles |
| 03/14/2002 | WO2002020011A2 A method for treating allergies using substituted pyrazoles |
| 03/14/2002 | WO2002020003A2 Use of carp inhibitors for the treatment of heart diseases |
| 03/14/2002 | WO2002020002A2 A method for treating allergies |
| 03/14/2002 | WO2002020000A2 Combined estrogen blockade of the breast with exemestane and raloxifene |
| 03/14/2002 | WO2002019998A2 A method of treating weight gain associated with atypical antipsychotic use |
| 03/14/2002 | WO2002019982A2 Cosmetic composition and method for reducing or preventing wrinkling |
| 03/14/2002 | WO2002019975A1 Hair growth stimulants |
| 03/14/2002 | WO2002019967A2 Substituted hydrazine derivatives |
| 03/14/2002 | WO2002019963A2 Synthetic erythropoiesis stimulating proteins |
| 03/14/2002 | WO2001082909A3 2-acyl indol derivatives and their use as anti-tumour agents |
| 03/14/2002 | WO2001079502A3 Vectors for gene therapy |
| 03/14/2002 | WO2001076644A3 Lipid-based systems for targeting diagnostic agents |
| 03/14/2002 | WO2001076555A3 Lipid-based drug delivery systems for topical application |
| 03/14/2002 | WO2001074790A3 Novel compounds for enhancing chemotherapy |
| 03/14/2002 | WO2001072290A3 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 03/14/2002 | WO2001070757A3 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 03/14/2002 | WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 03/14/2002 | WO2001070673A3 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 03/14/2002 | WO2001070668B1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 03/14/2002 | WO2001066553A3 Novel aryl fructose-1,6-bisphosphatase inhibitors |
| 03/14/2002 | WO2001064163A3 An improved herbal composition having antiallergic properties and a process for the preparation thereof |
| 03/14/2002 | WO2001064046A3 Method for isolating sponge collagen and producing nanoparticulate collagen, and the use thereof |
| 03/14/2002 | WO2001058921A9 Methods and compositions for generating angiostatin |
| 03/14/2002 | WO2001058918A3 Oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments |
| 03/14/2002 | WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001052826A3 Novel podophyllotoxin compositions |
| 03/14/2002 | WO2001051519A3 Potassium channel mutants of the saccharomyces cerevisiae yeast and the use thereof for the screening of eukaryotic potassium channels |
| 03/14/2002 | WO2001051512A3 Human and parasite orphan receptor proteins |
| 03/14/2002 | WO2001045715A3 Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain |
| 03/14/2002 | WO2001045684A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001045682A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001032161A3 Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| 03/14/2002 | WO2001032130A3 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 03/14/2002 | WO2001021651A3 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/14/2002 | WO2001020031A3 Polymorphisms in a klotho gene |
| 03/14/2002 | WO2001002018A3 Compounds that associate on the intermolecular level and aggregate bodies that contain them |
| 03/14/2002 | WO2000065028A9 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 03/14/2002 | WO2000056899A9 Dsp-2 dual-specificity map kinase phosphatase |